Last updated: August 28, 2026
Primaquine phosphate is an established, off-patent antimalarial with limited active-ingredient patent risk and greater commercial potential in pediatric, dispersible, taste-masked, stability-enhanced, and supply-chain-optimized formulations. The strongest opportunities are products that improve administration and access without changing the established primaquine dose, G6PD safety requirements, or radical-cure positioning.
What is the regulatory and commercial status of primaquine phosphate?
Primaquine phosphate is an oral 8-aminoquinoline used for radical cure of Plasmodium vivax and Plasmodium ovale malaria and for prevention of relapse. The phosphate salt is commonly supplied as a 26.3 mg tablet equivalent to 15 mg of primaquine base. Treatment duration and dose depend on patient weight, malaria species, age, and G6PD status.[1][2]
| Attribute |
Primaquine phosphate |
| Active ingredient |
Primaquine phosphate |
| Common strength |
26.3 mg salt, equivalent to 15 mg base |
| Dosage form |
Immediate-release oral tablet |
| Main use |
Radical cure and relapse prevention |
| Therapeutic class |
8-aminoquinoline antimalarial |
| Key safety requirement |
Quantitative or reliable G6PD assessment |
| Regulatory pathway for new generic products |
ANDA or applicable national generic pathway |
| Core active-ingredient patent risk |
Low for the legacy molecule |
| Main commercial barriers |
Small market, fragmented demand, G6PD safety, pediatric dosing |
| Main formulation opportunity |
Dispersible or age-appropriate oral dosage forms |
The product is primarily a public-health and infectious-disease medicine rather than a high-volume chronic therapy. Commercial demand is concentrated in malaria-endemic countries, travel medicine, military use, government tenders, hospitals, and global-health procurement.
In the United States, primaquine is a prescription product regulated through FDA drug-product and labeling requirements. CDC treatment guidance identifies primaquine as a principal option for preventing relapse in susceptible P. vivax and P. ovale infections, subject to G6PD testing and contraindication screening.[2]
What excipients are suitable for primaquine phosphate tablets?
A conventional immediate-release tablet can use a standard excipient system comprising a diluent, binder, disintegrant, lubricant, and optional film coat. The formulation should prioritize dose uniformity, rapid disintegration, chemical stability, and low manufacturing complexity.
Recommended immediate-release excipient architecture
| Formulation function |
Suitable excipient classes |
Commercial rationale |
| Diluent |
Microcrystalline cellulose, lactose, mannitol, dibasic calcium phosphate |
Controls tablet size and compressibility |
| Binder |
Povidone, copovidone, pregelatinized starch, low-substituted hydroxypropyl cellulose |
Improves granule and tablet strength |
| Disintegrant |
Crospovidone, croscarmellose sodium, sodium starch glycolate |
Supports rapid release |
| Glidant |
Colloidal silicon dioxide |
Improves powder flow |
| Lubricant |
Magnesium stearate, sodium stearyl fumarate |
Supports tableting and ejection |
| Film coating |
Hypromellose, polyethylene glycol, titanium dioxide, iron oxides |
Improves handling, identification, and swallowability |
| Taste masking |
Polymer film, ion-exchange resin, lipid coating, sweetener system |
Enables pediatric or dispersible products |
Primaquine is administered at a relatively low active dose, which makes content uniformity and blend segregation important. Direct compression is commercially attractive where powder flow and dose distribution are adequate. Wet granulation may provide better content uniformity and tablet robustness but increases process steps and moisture exposure.
The phosphate salt should be evaluated for compatibility with alkaline excipients, reducing sugars, moisture, and metal ions. Excipient selection should be based on impurity profiling, assay stability, dissolution, and tablet hardness rather than on generic platform formulation alone.
What pediatric formulations are protected by commercial opportunity?
Pediatric delivery is the clearest formulation opportunity. Primaquine dosing is weight-based, while many existing products are supplied as adult-strength tablets. Caregivers may need to split tablets, create extemporaneous suspensions, or administer crushed tablets. Those approaches can produce dose variability and poor acceptability.
High-value pediatric formats
Dispersible tablets
A dispersible tablet could be designed for rapid dispersion in a small volume of water. Suitable excipient systems may include mannitol for mouthfeel, crospovidone or croscarmellose sodium for rapid dispersion, and a polymeric taste-masking layer.
Commercial advantages include:
- Better weight-band dosing
- Lower dependence on tablet splitting
- Easier administration in field settings
- Reduced need for pharmacy compounding
- Potential alignment with pediatric procurement programs
The principal technical issue is taste. Primaquine's bitterness and possible metallic or astringent sensory profile can reduce adherence. Sweeteners and flavors alone may not provide sufficient masking. A coated multiparticulate or ion-exchange-resin system may provide stronger control.
Oral granules or sachets
Granules supplied in unit-dose sachets could support weight-based dosing and reduce tablet manipulation. Mannitol, sucrose, microcrystalline cellulose, starch, or polymeric granule systems may be used, subject to stability and microbial-control requirements.
Sachets offer advantages for humanitarian distribution because they can be packaged by dose band and administered with water or soft food. They also create a differentiated product without requiring a complex modified-release platform.
Oral suspension
A ready-to-use suspension could improve use in young children but presents higher manufacturing and distribution costs. The formulation would require:
- A suspension vehicle
- Wetting and suspending agents
- Preservative strategy
- Redispersibility control
- Container-closure compatibility
- In-use stability data
A dry powder for reconstitution may provide a better balance between pediatric usability and shelf life.
How can excipients improve primaquine phosphate taste and adherence?
Taste masking is commercially relevant because primaquine is often used in multi-day regimens, and adherence is central to relapse prevention. A film-coated adult tablet may be adequate for older patients but does not solve pediatric acceptability.
Three approaches are commercially plausible:
- Polymer coating of granules or drug particles.
- Ion-exchange-resin complexation.
- Lipid or lipid-polymer barriers combined with sweeteners and flavor.
Ion-exchange systems can reduce immediate bitterness but may affect dissolution and bioavailability. Polymer coatings can provide predictable release if coating thickness is controlled. Lipid systems may improve taste but can introduce manufacturing and stability complexity.
The formulation target should remain immediate release. A taste-masked product that delays or reduces primaquine exposure could create regulatory and clinical risk, particularly where the product is used with chloroquine for radical cure.
What formulation patents could protect a new primaquine phosphate product?
The legacy active ingredient is unlikely to support meaningful composition-of-matter exclusivity. Commercial protection would instead come from formulation, manufacturing, packaging, or combination claims.
Potential claim categories
| Claim category |
Potential strength |
Main vulnerability |
| New salt or polymorph |
Low to moderate |
Prior-art and obviousness challenges |
| Dispersible tablet |
Moderate |
Standard excipient combinations may be obvious |
| Taste-masked multiparticulate |
Moderate to strong |
Requires comparative sensory and dissolution data |
| Pediatric dose-band formulation |
Moderate |
Dose presentation may not be inventive alone |
| Dry powder for reconstitution |
Moderate |
Stability and reconstitution performance can support claims |
| Fixed-dose primaquine/chloroquine product |
Moderate |
Combination prior art and dose-ratio issues |
| Manufacturing process |
Moderate |
Must show reproducible technical advantage |
| Packaging for humidity protection |
Low to moderate |
Stronger if linked to demonstrated stability improvement |
| G6PD-testing-linked kit |
Variable |
Regulatory classification and combination-product issues |
A strong formulation patent would need more than a list of conventional excipients. Useful evidence could include superior impurity control, improved dissolution after storage, reduced bitterness, improved dose uniformity, or stability under tropical temperature and humidity conditions.
A patent directed only to “primaquine phosphate with a disintegrant and lubricant” would face a substantial obviousness risk. Claims should focus on defined excipient ranges, particle engineering, coating parameters, critical quality attributes, and measured performance.
When does primaquine phosphate lose exclusivity?
The active ingredient is a legacy antimalarial and is generally treated as off-patent. The practical market does not depend on exclusivity for the molecule. Any remaining protection would be product-specific and could involve a particular formulation, manufacturing process, combination, or regulatory exclusivity period.
| Exclusivity type |
Primaquine phosphate assessment |
| Composition-of-matter patent |
No meaningful current protection expected for the legacy molecule |
| Standard tablet formulation patent |
No broad blocking estate generally associated with the molecule |
| Method-of-use patent |
Potentially narrow and difficult to enforce against established malaria uses |
| Pediatric formulation patent |
Potential opportunity for a new entrant |
| Orphan exclusivity |
Generally not the primary U.S. commercial framework |
| Regulatory exclusivity |
Product-specific; must be checked against the applicable FDA record |
| Generic competition |
Expected where a qualifying reference product and market exist |
The relevant commercial question is not when the molecule loses exclusivity. It is whether a differentiated product can obtain procurement preference, regulatory advantages, or pricing power despite generic competition.
What is the Orange Book status of primaquine phosphate?
The FDA Orange Book should be reviewed by reference product, NDA, dosage form, and strength because listings are product-specific.[3] A generic primaquine phosphate tablet would normally seek approval through an ANDA referencing an approved immediate-release product where an appropriate reference standard is available.
For a new formulation, an applicant may need an NDA rather than an ANDA if the product differs materially in dosage form, route, formulation performance, or labeling. A new pediatric dispersible tablet, dry powder, or taste-masked multiparticulate may not qualify as a straightforward generic substitution if it lacks an appropriate reference product.
Paragraph IV and litigation risk
Primaquine phosphate has a lower Paragraph IV risk profile than newer branded products because the molecule and principal use are old. A Paragraph IV filing would be more likely to target a narrow formulation or method-of-use patent than a foundational active-ingredient patent.
The major legal scenarios are:
- ANDA approval against an unprotected immediate-release reference product.
- Paragraph IV certification against a listed formulation patent.
- Section viii carve-out for an unapproved use, where legally available.
- NDA development for a differentiated pediatric or combination product.
- Patent protection for a proprietary taste-masking or manufacturing process.
No broad, commercially dominant patent estate is generally associated with conventional primaquine phosphate tablets. Patent risk must still be screened against the specific reference product and jurisdiction before launch.
Which companies are challenging or competing with primaquine phosphate?
Competition comes from three groups: generic primaquine suppliers, alternative antimalarial products, and public-sector manufacturers.
Direct competitors
Direct competitors supply primaquine phosphate tablets or equivalent primaquine products. They compete primarily on:
- Tender price
- WHO or national regulatory qualification
- Supply reliability
- Packaging
- Strength availability
- Pediatric usability
- Stability in hot and humid climates
Therapeutic competitors
Tafenoquine is the principal modern therapeutic comparator for radical cure of P. vivax. It has a longer half-life and can support a shorter regimen, but it requires appropriate G6PD assessment and has different age, safety, dosing, and regulatory constraints.[2][4]
| Attribute |
Primaquine phosphate |
Tafenoquine |
| Drug class |
8-aminoquinoline |
8-aminoquinoline |
| Regimen |
Multi-day |
Single-dose or short-course approach, depending on product and indication |
| Formulation opportunity |
Pediatric dispersible, granules, suspension |
Adult and adolescent products, diagnostic-linked use |
| Manufacturing maturity |
High |
Lower relative legacy maturity |
| Generic pressure |
High |
More limited, product-dependent |
| Main differentiator |
Cost and pediatric flexibility |
Regimen convenience |
| Safety gate |
G6PD testing |
G6PD testing |
Primaquine retains a cost and supply-chain advantage in many settings. Tafenoquine competes on adherence and convenience rather than on formulation simplicity.
What manufacturing and intellectual-property barriers affect commercial entry?
The manufacturing process is relatively accessible for a conventional tablet, but commercial success depends on quality-system execution. Relevant technical barriers include:
- Assay and content-uniformity control at low dose
- Control of phosphate-salt particle size
- Moisture protection
- Dissolution after accelerated storage
- Tablet splitting performance
- Taste masking without delayed release
- Stability in climatic zones III and IV
- Reliable supply of pharmaceutical-grade active ingredient
- Child-resistant and unit-dose packaging
For a pediatric product, the critical quality target is dose accuracy across the intended weight bands. A product that requires caregivers to estimate partial doses may lose its commercial advantage.
Manufacturing IP can be stronger when it is tied to a defined process, such as spray coating, hot-melt taste masking, fluid-bed granulation, or moisture-barrier packaging. Process claims should be supported by reproducibility and comparative data.
What licensing deals and commercial partnerships are realistic?
Publicly visible licensing activity around conventional primaquine phosphate is limited. The most realistic partnership structures are:
Public-sector supply agreements
Government tenders and global-health procurement can provide volume but usually impose strict price and delivery requirements. A supplier with a pediatric dosage form, WHO prequalification, or strong tropical stability data may obtain an advantage.
Technology licensing
A specialty formulation company could license:
- Taste-masked multiparticulates
- Dispersible-tablet technology
- Dry powder reconstitution technology
- Humidity-resistant packaging
- Pediatric dose-band platforms
The licensor should seek milestone payments tied to regulatory approval and procurement qualification rather than rely only on royalty economics.
Diagnostic-linked commercialization
Because G6PD status determines eligibility and dosing strategy, a product could be commercialized with access to G6PD testing. A bundled product must be reviewed for regulatory, reimbursement, procurement, and combination-product implications.
Combination products
A fixed-dose primaquine and chloroquine product could simplify radical-cure administration, but the dose flexibility and prescribing requirements of both components may limit the practicality of a single fixed ratio. A co-pack may be easier to develop and could preserve dosing flexibility.
What revenue exposure and generic launch scenarios exist?
Primaquine is unlikely to support blockbuster revenue. The commercial case depends on differentiated access, geographic focus, and procurement economics.
| Launch scenario |
Product |
Commercial profile |
Main risk |
| Low-cost generic |
26.3 mg immediate-release tablet |
Lowest development cost; price competition |
Thin margins |
| Premium generic |
Film-coated, stability-optimized tablet |
Modest differentiation |
Limited willingness to pay |
| Pediatric dispersible |
Weight-band dispersible tablet |
Strongest formulation opportunity |
Taste and bioequivalence |
| Dry powder |
Reconstituted pediatric suspension |
Useful in low-resource settings |
Packaging and stability costs |
| Co-pack |
Primaquine plus chloroquine |
Administration convenience |
Labeling and dose flexibility |
| Diagnostic-linked product |
Primaquine plus G6PD access |
Potential procurement differentiation |
Partnership and regulatory complexity |
A generic adult tablet may launch quickly but will face price erosion. A pediatric product can command stronger strategic value if it reduces tablet splitting, improves adherence, and meets procurement standards. Revenue exposure is therefore more likely to come from volume expansion and preferred-supplier status than from high unit pricing.
How strong is the primaquine phosphate patent estate?
The patent estate is weak for the conventional active ingredient and standard immediate-release tablet. A new entrant can create a stronger, narrower estate around a technically differentiated product.
Patent-strength assessment
| Estate component |
Assessment |
| Active ingredient |
Weak or expired legacy protection |
| Conventional tablet |
Weak |
| Pediatric dispersible formulation |
Moderate if supported by performance data |
| Taste-masked multiparticulate |
Moderate to strong |
| Fixed-dose combination |
Moderate, subject to prior art |
| Manufacturing process |
Moderate if process-specific and reproducible |
| Packaging and stability |
Narrow but commercially useful |
| Method of use |
Limited by longstanding clinical use |
The most defensible strategy is a layered portfolio: composition claims for the taste-masked system, dependent claims covering excipient ratios and particle size, process claims, and use or packaging claims directed to pediatric administration and tropical stability.
Key Takeaways
- Primaquine phosphate is an established, low-exclusivity antimalarial with limited core patent risk.
- The strongest commercial opportunity is a pediatric dispersible, taste-masked, or dry-powder formulation.
- Conventional excipients are adequate for an adult immediate-release tablet, but low-dose content uniformity and moisture stability require process control.
- G6PD testing remains a central safety and commercialization issue.
- Tafenoquine is the principal therapeutic comparator because it competes on regimen convenience.
- A standard generic tablet will face price pressure and likely limited margins.
- A differentiated formulation can support regulatory, procurement, and patent value if it demonstrates superior taste, dose accuracy, dissolution, or tropical stability.
- A co-pack with chloroquine may be more practical than a fixed-dose combination because it preserves dosing flexibility.
- Paragraph IV risk is likely to focus on any new formulation patent rather than the legacy primaquine molecule.
- Licensing value is most credible for pediatric delivery technology, taste masking, packaging, or diagnostic-linked access.
FAQs
Can primaquine phosphate be formulated as a chewable tablet?
Yes. A chewable tablet is technically feasible, but bitterness, mouthfeel, dose uniformity, and pediatric acceptability must be controlled. Taste masking is likely to be more important than tablet hardness.
Is primaquine phosphate suitable for an orally disintegrating tablet?
It can be considered, but an orally disintegrating tablet may expose the patient to bitterness before swallowing. A coated or multiparticulate approach may be more suitable than an uncoated ODT.
Can primaquine phosphate and chloroquine be sold in one package?
Yes. A co-pack can preserve independent dosing while simplifying radical-cure administration. A fixed-dose combination would require stronger evidence that the dose ratio is appropriate across patient populations.
Does primaquine phosphate require a new clinical trial for a new excipient formulation?
Not necessarily. A conventional generic may rely on pharmaceutical equivalence and bioequivalence. A materially different pediatric or modified formulation may require additional clinical, biopharmaceutic, or acceptability evidence.
What is the most valuable patent claim for a new primaquine product?
A claim covering a validated taste-masked pediatric formulation with defined particle-size, coating, dissolution, and stability parameters is likely more commercially valuable than a broad claim to conventional tablet excipients.
References
- U.S. Food and Drug Administration. (n.d.). Primaquine phosphate tablets prescribing information. DailyMed.
- Centers for Disease Control and Prevention. (2024). Malaria: Treatment tables and clinical guidance.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- World Health Organization. (2023). WHO guidelines for malaria. World Health Organization.
- U.S. Food and Drug Administration. (2013). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA.
